에 대한 최신 뉴스 Intuitive Surgical (NASDAQ:ISRG) 주식

Intuitive Surgical

Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed more than 8,600 da Vinci systems in hospitals worldwide, with more than 5,000 installations in the US and a growing number in emerging markets.

Equities

News

Markets

ISRG

QUBT

TSLA

수요일(15일) 미국 증시는 나스닥 종합지수가 2.45% 상승한 19,511.23포인트 S&amp;P 500 지수가 1.8% 상승한 5,949.91포인트를 기록하며 강세를 보였다. 수요일 주목받은 주식: 퀀텀 컴퓨팅, TSMC, 메타, 인튜이티브 및 테슬라

수요일 주목받은 주식: 퀀텀 컴퓨팅, TSMC, 메타, 인튜이티브 및 테슬라

Analyst Color

Long Ideas

Sector ETFs

Analyst Ratings

Tech

Trading Ideas

ETFs

ABBNY

NVDA

PATH

PLTR

ZBRA

미국의 경쟁력은 2025년에 네 가지 주요 투자 테마인 에너지 독립, 방산 혁신, 인프라 및 자동화가 포트폴리오 성장을 강화할 태세를 갖추면서 중심 무대로 떠오른다. 스콧 헬프스타인(Scott Helfstein)이 이끄는 글로벌 X의 2025년 투자 전망은 이러한 변혁적인 트렌드를 향후 1년 동안의 회복력의 중요한 동력으로 강조하고 있다.

2025 투자 테마: 인공지능, 에너지 및 방산이 미국 시장을 재정의

Exclusives

INSM

매주, ‘벤징가의 스톡 위스퍼 지수(Benzinga&#39;s Stock Whisper Index)&#39;는 독점 데이터(proprietary data)와 패턴 인식의 조합을 사용하여 표면 바로 아래에서 주목을 받을 만한 주식 5종목을 소개한다. 투자자들은 가치가 저평가된, 관심이 적은, 새로운 주식들을 항상 찾고 있다. 소매 거래자들이 사용할 수 있는 방법은 무수히 많기 때문에 새로운 기회를 발견하고 특정 주식이 관심을 가져야 하는 이유를 이해하기 위해 풍부한 정보를 조사하는 것이 어려운 경우가 많다.

벤징가의 &#39;스톡 위스퍼&#39; 지수: 인스메드, 인튜이티브 서지컬, 뮬러 인더스트리즈 및 2종목

Intuitive Surgical Inc

The U.S. stock market experienced a robust session with the Nasdaq Composite climbing 2.45% to 19,511.23 and the S&amp;P 500 rising by 1.8% to 5,949.91. The Dow Jones Industrial Average also saw gains, increasing by 1.65% to 43,221.55. 
These are the top stocks that gained the attention of retail traders and investors throughout the day:
Quantum Computing Inc.
Quantum Computing Inc. shares soared by 55.45%, closing at $11.55. The stock reached an intraday high of $11.60 and a low of $8.51, with a 52-week range of $27.15 to $0.35. The surge followed <a href="https://www.benzinga.com/25/01/43004816/whats-going-on-with-quantum-computing-stock-today">NVIDIA Corp.&#8217;s announcement</a> of its inaugural Quantum Day, scheduled for March 20 during the GTC 2025 event. This announcement comes shortly after CEO Jensen Huang mentioned that practical quantum computing might still be two decades away. Additionally, Microsoft Corporation&#8217;s plans to make its business clients &#8220;quantum-ready&#8221; by 2025 added to the excitement.
Taiwan Semiconductor Manufacturing Co.
Taiwan Semiconductor&#8217;s stock rose by 2.61%, closing at $206.80. The day&#8217;s trading saw a high of $209.04 and a low of $199.35, with a 52-week range of $222.20 to $100. The company is set to release its fourth-quarter financial results, with analysts expecting a fifth consecutive revenue beat. The anticipated revenue is $26.28 billion, up from $19.62 billion in the same quarter last year, driven by strong semiconductor demand and <a href="https://www.benzinga.com/25/01/43015316/taiwan-semiconductor-q4-earnings-preview-analysts-expect-fifth-straight-beat-will-investors-get-comments-on-trump-impact">potential benefits</a> from the new U.S. administration.
Meta Platforms Inc.
Meta Platforms saw a 3.85% increase, closing at $617.12. The stock hit an intraday high of $622.46 and a low of $606.50, with a 52-week range of $638.40 to $358.61. An internal memo revealed <a href="https://www.benzinga.com/media/25/01/42995912/meta-plans-to-cut-5-of-staff-backfill-roles-in-2025-says-internal-memo">plans for performance-based job cuts</a>, aiming for a 10% &#8220;non-regrettable attrition&#8221; rate by the end of the current performance cycle. This strategy involves classifying employees into performance tiers based on their contributions over the past year.
Intuitive Surgical Inc.
Intuitive Surgical&#8217;s shares jumped by 7.65%, closing at $580.11. The stock reached an intraday high of $584.60 and a low of $549.17, with a 52-week range of $584.60 to $355.17. The increase followed the company&#8217;s&nbsp;<a href="https://www.benzinga.com/news/earnings/25/01/43007218/why-intuitive-surgical-shares-are-surging-wednesday">preliminary fourth-quarter results</a>, which showed expected revenue of approximately $2.41 billion, surpassing analyst estimates of $2.2 billion. The company also reported a significant growth in da Vinci procedures and system placements.
Tesla, Inc.
Tesla&#8217;s stock rose by 8.04%, closing at $428.22. The day&#8217;s trading saw a high of $429.80 and a low of $405.66, with a 52-week range of $488.54 to $138.80. The rise was influenced by recent data from Kelley Blue Book ranking Tesla&#8217;s Model Y and Model 3 as the top-selling electric vehicles. Despite selling about 37,000 fewer cars in 2024 compared to 2023, Tesla <a href="https://www.benzinga.com/25/01/43014719/whats-going-on-with-tesla-shares-wednesday">maintained its lead</a> in the EV market, with increased competition noted as a factor.
Image via Shutterstock
Prepare for the day&#8217;s trading <a href="https://editorial.benzinga.com/wp-admin/Premarket%20Movers%20&amp;%20News">with top premarket movers and news</a> by Benzinga.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/01/43018900/from-adani-to-nikola-how-hindenburg-research-reshaped-short-selling-before-its-final-bow">From Adani To Nikola: How Hindenburg Research Reshaped Short-Selling Before Its Final Bow</a></li>
</ul>
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>

Quantum Computing, Taiwan Semiconductor, Meta, Intuitive Surgical, And Tesla: Why These 5 Stocks Are On Investors' Radars Today

Wall Street staged a strong rebound on Wednesday, as mixed inflation data bolstered investor confidence in the Federal Reserve's continuation of easing cycle in 2025, <a href="https://www.benzinga.com/economics/macro-economic-events/25/01/43001512/inflation-rises-to-29-in-december-core-slows-yet-rising-energy-costs-put-feds-target-at-risk">easing recent market anxieties.</a>
The headline Consumer Price Index rose 2.9% year-over-year in December, up from November&#8217;s 2.7% and aligning with economist forecasts. On a monthly basis, headline inflation increased by 0.4%, up from November&#8217;s 0.3%, marking the sharpest monthly rise since March 2024.
The inflation report strengthened market expectations for Fed rate cuts in 2025. The probability of a rate cut by June climbed to 63%, up from 55% the previous day, with December futures now pricing in a 50% chance of two rate cuts.
The S&amp;P 500 advanced 1.5% by midday trading in New York, and the Dow Jones followed suit with a similar gain, both supported by strength in financial stocks. The Nasdaq 100 outperformed, rising 1.9%, while small-cap stocks posted a 1.7% gain.
Key financial giants, including JPMorgan Chase &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>), Citigroup Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/C#NYSE">C</a>), Goldman Sachs Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>), Wells Fargo &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFC#NYSE">WFC</a>), Bank of New York Mellon Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BK#NYSE">BK</a>), and BlackRock Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLK#NYSE">BLK</a>), exceeded Wall Street's <a href="https://www.benzinga.com/news/earnings/25/01/43007354/big-banks-crush-q4-earnings-forecasts-financial-stocks-set-for-biggest-1-day-rally-since-trumps-election">fourth-quarter 2024 earnings expectations.</a>
The Financial Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>) surged nearly 2.2%, leading all S&amp;P 500 sectors and recording its strongest one-day gain in over two months.
In the bond market, yields on the 2-year Treasury note, which is highly sensitive to interest rate expectations, fell 9 basis points to 4.28%, while 30-year yields dropped 8 basis points to 4.89%. The iShares 20+ Year Treasury Bond ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLT#NASDAQ">TLT</a>) gained 1.3% as bond prices rose.
The U.S. Dollar Index (DXY), as tracked by the Invesco DB USD Index Bullish Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UUP#NYSE">UUP</a>), remained flat, with dollar strength against the euro offset by weakness versus the yen.
West Texas Intermediate — as tracked by the United States Oil Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USO#NYSE">USO</a>) — rallied 2%, hitting $80 a barrel during the day amid a stronger-than-expected drop in commercial crude stocks last week.
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) jumped 2.6%, nearing $99,000, buoyed by optimism surrounding potential Fed rate cuts. Meanwhile, gold, tracked by the SPDR Gold Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLD#NYSE">GLD</a>), gained 0.5%. 
<h1 class="wp-block-heading">Wednesday&#8217;s Performance In Major U.S. Indices, ETFs</h1>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day % chg</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>21,142.06</td>
<td>1.9%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,257.59</td>
<td>1.7%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,932.76</td>
<td>1.5%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>43,153.53</td>
<td>1.5%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 12:15 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011525&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) rose 1.5% to $590.96.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>)&nbsp;rose 1.5% to $431.31.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) rallied 1.9% to $514.49.</li>
<li>The&nbsp;iShares Russell 2000 ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) increased 1.8% to $223.77.</li>
<li>The&nbsp;Financial Select Sector SPDR Fund outperformed, up 1.2%; the&nbsp;Consumer Staples Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>) lagged, down 0.3%.</li>
</ul>
<h3 class="wp-block-heading">Wednesday&#8217;s Stock Movers</h3>
<ul>
<li>Citigroup Inc. rallied over 7%, in reaction to stronger-than-expected earnings, marking the strongest performance within the S&amp;P 500 index.</li>
<li>Intuitive Surgical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) rose 6.9% after RBC raised its 12-month price target to $641. </li>
<li>Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) shares climbed more than 5% after RBC increased its price target for the stock from $313 to $440, while reaffirming its outperform rating.</li>
</ul>
Read Now: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43006771/bitcoin-up-to-99000-is-loving-inflation-data-release-xrp-dogecoin-follow-higher">Bitcoin Up To $99,000 &#8216;Is Loving&#8217; Inflation Data Release, XRP, Dogecoin Follow Higher</a></li>
</ul>
Photo: Shutterstock

Large Cap

Macro Economic Events

Bonds

Broad U.S. Equity ETFs

Commodities

Econ #s

Economics

$BTC

SPDR Dow Jones Industrial Average ETF Trust

iShares Trust Barclays 20+ Year Treasury Bond Fund

PowerShares DB US Dollar Index Bullish Fund

Wall Street Rallies As Treasury Yields Fall, Banks Smash Q4 Earnings, Oil Hits $80: What's Driving Markets Wednesday?

Intuitive Surgical Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) shares are trading higher Wednesday after the company reported preliminary financial results <a href="https://www.benzinga.com/pressreleases/25/01/g43002040/intuitive-announces-preliminary-fourth-quarter-and-full-year-2024-results">for the fourth quarter</a>. 
What Happened: Intuitive Surgical said it expects to report fourth-quarter revenue of approximately $2.41 billion, versus analyst estimates of $2.2 billion, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>. 
The company expects worldwide da Vinci procedures&nbsp;to grow approximately&nbsp;18%&nbsp;compared with the&nbsp;fourth quarter&nbsp;of 2023. Intuitive Surgical expects to report 493 da Vinci surgical systems placed in the quarter. 
&#8220;We are pleased with customer adoption of da Vinci 5, Ion, and SP during the quarter and full year. We remain focused on delivering the goals we share with our customers, centered on improving patient outcomes,&#8221; said Gary Guthart, CEO of Intuitive Surgical. 
Intuitive Surgical released its preliminary results ahead of a presentation Wednesday at the 2025 J.P. Morgan Healthcare Conference. The company is scheduled to report its full fourth-quarter earnings results on Jan. 23. Intuitive Surgical noted that it will discuss the quarter in more detail at that time. 
See Also:<a href="https://www.benzinga.com/economics/macro-economic-events/25/01/43001512/inflation-rises-to-29-in-december-core-slows-yet-rising-energy-costs-put-feds-target-at-risk"> Inflation Rises To 2.9% In December: Core Slows, Yet Rising Energy Costs Put Fed&#8217;s Target At Risk</a>
<h3 class="wp-block-heading">How To Buy ISRG Stock</h3>
By now you're likely curious about how to participate in the market for Intuitive Surgical &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share. In the case of Intuitive Surgical, which is trading at $538.88 as of publishing time, $100 would buy you 0.19 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
ISRG Price Action: <a href="https://www.benzinga.com/quote/ISRG" target="_blank" rel="noreferrer noopener">Intuitive Surgical shares</a> were up 6.40% at $573.40 at the time of publication Wednesday, according to <a href="https://benzinga.grsm.io/gxjhpowx7zks" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Photo: courtesy of Intuitive Surgical.

Earnings

Guidance

Movers

Why Intuitive Surgical Shares Are Surging Wednesday

Major indices rallied on Wednesday after December inflation data showed underlying price pressures slowing, reducing fears of a prolonged pause in interest rate cuts <a href="https://www.benzinga.com/economics/macro-economic-events/25/01/43001512/inflation-rises-to-29-in-december-core-slows-yet-rising-energy-costs-put-feds-target-at-risk">by the Federal Reserve. </a>
The headline Consumer Price Index rose 2.9% year-over-year in December, up from November's 2.7%, matching economist forecasts. On a monthly basis, headline inflation increased 0.4%, accelerating from the 0.3% surge in November and marking the largest monthly rise since March 2024.
Core inflation, which excludes volatile food and energy prices, rose 3.2% year-over-year, slightly below the expected 3.3%. Month-over-month, core prices gained 0.2%, in line with forecasts.
The inflation data boosted expectations for Fed rate cuts in 2025. The probability of a rate cut by June rose to 68% from 55% the previous day, with December futures now indicating a 58% chance of two cuts by year-end.
<h3 class="wp-block-heading">Wall Street Gains As Bond Yields Retreat, Financial Stocks Soar</h3>
The S&amp;P 500 index – as tracked by the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) – surged 1.5% in early New York trading, led by financial stocks after major banks reported strong fourth-quarter earnings.
JPMorgan Chase &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>), Citigroup Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/C#NYSE">C</a>), Goldman Sachs Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>), Wells Fargo &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFC#NYSE">WFC</a>), Bank of New York Mellon Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BK#NYSE">BK</a>) and BlackRock Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLK#NYSE">BLK</a>) all topped earnings forecasts for the fourth quarter and released upbeat guidance, reiterating that the financial sector thrived heading to the end of last year.
The Financial Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>) rose 2.2%, leading all S&amp;P 500 sectors, while the SPDR S&amp;P Regional Banking ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KRE#NYSE">KRE</a>) jumped 3.4%, reflecting strong performance among regional banks.
The Dow rose 1.6%, while the Russell 2000 index outperformed, climbing 2.6%. Tech stocks, tracked by the Invesco QQQ Trust, Series 1 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), gained 1.7%, boosted by falling Treasury yields.
Yields on the policy-sensitive 2-year Treasury note fell 9 basis points to 4.27%, while 30-year yields dropped 9 basis points to 4.88%. The iShares 20+ Year Treasury Bond ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLT#NASDAQ">TLT</a>) gained 1.6% as bond prices rallied.
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) rose 2% to over $99,000, supported by rising hopes for Fed rate cuts. Gold, tracked by the SPDR Gold Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLD#NYSE">GLD</a>), added 0.5%.
<h3 class="wp-block-heading">Top Movers</h3>
S&amp;P 500 Gainers:
<ul>
<li>Texas Pacific Land Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPL#NYSE">TPL</a>): +5.85%</li>
<li>BlackRock Inc.: +5.54%</li>
<li>Assurant Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIZ#NYSE">AIZ</a>): +5.49%</li>
<li>Bio-Techne Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TECH#NASDAQ">TECH</a>): +5.36%</li>
<li>Citigroup Inc.: +5.16%</li>
</ul>
Nasdaq 100 Movers:
<ul>
<li>Copart Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRT#NASDAQ">CPRT</a>): +4.62%</li>
<li>Intuitive Surgical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>): +4.60%</li>
<li>AppLovin Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>): +4.43%</li>
<li>Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>): +4.30%</li>
<li>The Trade Desk Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>): +3.39%</li>
</ul>
Top Gainers In The Invesco KBW Bank ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KBWB#NYSE">KBWB</a>):
<ul>
<li>Citigroup Inc.: +5.27%</li>
<li>Wells Fargo &amp; Co.: +4.80%</li>
<li>Bank of New York Mellon Corp.: +4.35%</li>
<li>Western Alliance Bancorp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAL#NYSE">WAL</a>): +4.13%</li>
<li>Goldman Sachs Group Inc.: +4.02%</li>
</ul>
Read now: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43000684/jpmorgan-q4-earnings-shine-investment-banking-revenue-jumps-46-yy-jamie-dimon-says-inflation-may-persist-for-some-time">JPMorgan Chase Q4 Earnings: Investment Banking Revenue Jumps 46%, CEO Jamie Dimon Says &#8216;Inflation May Persist For Some Time&#8217;</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Small Cap

Federal Reserve

CPRT

KBWB

TECH

Stocks Rise On Core Inflation Slowdown, Banks Rally After Strong Q4 Earnings, Treasury Yields Plummet

WIIM

Intuitive Surgical shares are trading higher after the company reported strong preliminary Q4 results.

Intuitive Prelim. Q4 Results; Q4 Worldwide Da Vinci Procedures Grew Approximately 18% YoY, Da Vinci System Placements Totaled 493

Intuitive Sees Prelim. Q4 Revenue ~$2.41B vs $2.204B Est.; FY24 Revenue $8.35B

Scorpion Capital, on Friday, disclosed a short seller report on TransMedics Group Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>), accusing the organ transplant technology company of fraudulent practices, including kickbacks, billing fraud and <a href="https://www.benzinga.com/quote/TMDX" target="_blank" rel="noreferrer noopener">unreported device failures</a>.
Scorpion alleges that TransMedics engages in &#8220;mafia-style&#8221; practices, including coercion, billing fraud, and the manipulation of organ allocation, operating under the guise of a legitimate medical device company.
The report sets a price target of $0.
The company said the allegations are inaccurate and misleading. &#8220;We strongly believe that the claims made in the Scorpion Capital report have no merits and were primarily intended to manipulate the <a href="https://www.benzinga.com/pressreleases/25/01/n42940808/transmedics-responds-to-inaccurate-and-misleading-claims-in-recent-short-seller-report" target="_blank" rel="noreferrer noopener">market for financial gains</a>,&#8221; TransMedics said in a statement.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/management/24/12/42290942/transmedics-ushers-in-new-cfo-tightens-2024-revenue-goals" rel="noreferrer noopener">TransMedics Ushers In New CFO, Tightens 2024 Revenue Goals</a>
The report said TransMedics operates like an airline with a medical device component, trading at an expensive valuation of seven times its last 12 months&#8217; revenue.
By a more relevant metric, enterprise value to product sales, the ratio is 10 times – which Scorpion Capital describes as extraordinarily high, especially <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41608129/organ-transplant-medtech-transmedics-q3-performance-disappoints-analyst-outlines-in" target="_blank" rel="noreferrer noopener">as sales are declining</a>.
This makes TransMedics the most expensive mid-cap medtech company in the U.S. and the third-highest overall, behind Intuitive Surgical Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) and Glaukos Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>), according to Scorpion Capital. 
Even at a more reasonable multiple of 5 times product sales, TransMedics&#8217; stock would drop to the $30 range.
The company has no free cash flow and only recently turned slightly profitable, a trend likely to reverse with declining sales.
Scorpion stated in its report, &#8220;TransMedics is the most extreme and grotesque healthcare fraud we have encountered, not only for its scale, but because it is predicated on the exploitation of the most vulnerable patients &#8212; the terminally ill, desperate for an organ.&#8221;
The short seller <a target="_blank" href="https://scorpionreports.s3.us-east-2.amazonaws.com/TMDX.pdf" rel="noreferrer noopener">alleged</a> that TransMedics &#8220;pushes unsafe, damaged organs rejected by reputable centers, as an unplaced organ means loss of device and aircraft fees, with TransMedics allegedly concealing adverse organ information.&#8221;
Scorpion Capital announced plans to file a Citizen Petition with the FDA, requesting the suspension of Premarket Approval (PMA) for TransMedics&#8217; Organ Care System (OCS). The short seller also said it intends to send a public letter to members of Congress probing abuses in the U.S. organ transplant system.
In April, the FDA granted PMA to the OCS Heart System for use with organs from donors after circulatory death, following a PMA approval of the System after brain death received <a href="https://www.benzinga.com/pressreleases/22/04/n26862717/transmedics-receives-fda-pma-approval-of-ocs-dcd-heart-indication" target="_blank" rel="noreferrer noopener">in September 2021</a>.
Price Action: TMDX stock is down 12.6% at $60.10 at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/42949261/eli-lilly-scoops-up-scorpion-therapeutics-early-stage-cancer-program-for-25-billion" target="_blank" rel="noreferrer noopener">Eli Lilly Scoops Up Scorpion Therapeutics&#8217; Early-Stage Cancer Program For $2.5 Billion</a></li>
</ul>
Photo: Tigarto/Shutterstock.com

Health Care

General

GKOS

TMDX

Short Seller Accuses TransMedics Of 'Mafia Style' Scheme, Organ Transplant Company Says Short Seller Manipulating Market

Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) has outperformed the market over the past 10 years by 13.26% on an annualized basis producing an average annual return of 24.63%. Currently, Intuitive Surgical has a market capitalization of $185.93 billion. 
Buying $100 In ISRG: If an investor had bought $100 of ISRG stock 10 years ago, it would be worth $913.28 today based on a price of $522.00 for ISRG at the time of writing.
<h3>Intuitive Surgical's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1735740008_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $100 In This Stock 10 Years Ago, You Would Have This Much Today

Deep-pocketed investors have adopted a bearish approach towards Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in ISRG usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 8 extraordinary options activities for Intuitive Surgical. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 0% leaning bullish and 87% bearish. Among these notable options, 5 are puts, totaling $161,200, and 3 are calls, amounting to $223,830.
<h3>Predicted Price Range</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $310.0 and $560.0 for Intuitive Surgical, spanning the last three months.
<h3>Volume &amp; Open Interest Development</h3>
In today's trading context, the average open interest for options of Intuitive Surgical stands at 128.0, with a total volume reaching 495.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Intuitive Surgical, situated within the strike price corridor from $310.0 to $560.0, throughout the last 30 days.
<h3>Intuitive Surgical Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734623181_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ISRG</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$229.5</td>
<td>$225.5</td>
<td>$225.5</td>
<td>$310.00</td>
<td>$112.7K</td>
<td align="right">112</td>
<td align="right">5</td>
</tr>
<tr>
<td>ISRG</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/18/26</td>
<td>$110.5</td>
<td>$107.3</td>
<td>$107.3</td>
<td>$540.00</td>
<td>$75.1K</td>
<td align="right">217</td>
<td align="right">36</td>
</tr>
<tr>
<td>ISRG</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$37.2</td>
<td>$35.1</td>
<td>$35.97</td>
<td>$560.00</td>
<td>$35.9K</td>
<td align="right">149</td>
<td align="right">11</td>
</tr>
<tr>
<td>ISRG</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$32.9</td>
<td>$31.9</td>
<td>$32.9</td>
<td>$530.00</td>
<td>$32.9K</td>
<td align="right">34</td>
<td align="right">161</td>
</tr>
<tr>
<td>ISRG</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$32.9</td>
<td>$31.9</td>
<td>$32.9</td>
<td>$530.00</td>
<td>$32.9K</td>
<td align="right">34</td>
<td align="right">114</td>
</tr>
</tbody>
</table>

<h3>About Intuitive Surgical</h3>
Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed more than 8,600 da Vinci systems in hospitals worldwide, with more than 5,000 installations in the US and a growing number in emerging markets.
<h3>Present Market Standing of Intuitive Surgical</h3>
<ul>
<li>Currently trading with a volume of 282,168, the ISRG's price is up by 1.66%, now at $535.2. </li>
<li>RSI readings suggest the stock is currently may be approaching oversold.</li>
<li>Anticipated earnings release is in 33 days.</li>
</ul>
<h3>What Analysts Are Saying About Intuitive Surgical</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $618.2.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Showing optimism, an analyst from Morgan Stanley upgrades its rating to Overweight with a revised price target of $650. 
&#x2A; An analyst from Stifel has decided to maintain their Buy rating on Intuitive Surgical, which currently sits at a price target of $610. 
&#x2A; An analyst from BTIG has decided to maintain their Buy rating on Intuitive Surgical, which currently sits at a price target of $561. 
&#x2A; An analyst from Truist Securities persists with their Buy rating on Intuitive Surgical, maintaining a target price of $640. 
&#x2A; An analyst from Wells Fargo persists with their Overweight rating on Intuitive Surgical, maintaining a target price of $630. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Intuitive Surgical options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

Behind the Scenes of Intuitive Surgical's Latest Options Trends

Truist Securities analyst Richard Newitter maintains Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) with a Buy and raises the price target from $570 to $640.

Price Target

Truist Securities Maintains Buy on Intuitive Surgical, Raises Price Target to $640

Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) has outperformed the market over the past 5 years by 8.96% on an annualized basis producing an average annual return of 22.57%. Currently, Intuitive Surgical has a market capitalization of $194.20 billion. 
Buying $100 In ISRG: If an investor had bought $100 of ISRG stock 5 years ago, it would be worth $277.84 today based on a price of $545.23 for ISRG at the time of writing.
<h3>Intuitive Surgical's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734364809_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Intuitive Surgical 5 Years Ago Would Be Worth This Much Today

Citigroup analyst Joanne Wuensch maintains Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) with a Buy and raises the price target from $567 to $640.

Citigroup Maintains Buy on Intuitive Surgical, Raises Price Target to $640

U.S. competitiveness takes center stage in 2025 with four key investment themes—energy independence, defense innovation, infrastructure, and automation—poised to bolster portfolio growth. Global X's 2025 Investment Outlook, led by Scott Helfstein, highlights these transformative trends as critical drivers of resilience <a href="https://www.benzinga.com/topic/us-economy">in the coming year.</a>
<h2 class="wp-block-heading">Infrastructure Gets A Glow-Up</h2>
America&#8217;s infrastructure renaissance is going full throttle, with $700 billion in spending set to energize construction, equipment, and materials companies. This may bode well for investors in the Industrial Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLI#NYSE">XLI</a>).
These stalwarts of the old economy are reinventing themselves with cutting-edge tech to expand margins—all while trading at attractive valuations compared to the broader S&amp;P 500.
<h2 class="wp-block-heading">The Defense Play: Beyond Jets &amp; Ships</h2>
Global tensions are driving a pivot from traditional defense platforms to high-tech solutions like AI-driven drones and cybersecurity systems. 
Palantir Technologies Inc&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) Artificial Intelligence Platform and International Business Machines Corp&#8216;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>) WatsonX AI come to mind here.
Defense revenues are expected to jump nearly 10%, with margins climbing from 5.2% to 7.6%. Success will favor those adopting automation and next-generation technologies in this competitive landscape.
Read Also: <a href="https://www.benzinga.com/news/small-cap/24/12/42438879/manufacturing-tariffs-small-cap-could-steal-the-show-in-2025">Manufacturing Comeback? Strategist Expects Tariffs To Help Small-Cap Stocks But Weigh On Consumers</a>
<h2 class="wp-block-heading">Automation &amp; Onshoring: A Tech Revolution</h2>
With the U.S. accelerating its onshoring efforts, automation and AI are emerging as the driving forces powering the shift.
Software companies and data centers are prepping for a revenue surge, with mega-cap tech upping its spending on data centers to $250 billion in 2025. 
Robotics and IoT hardware could also rebound from a sales plateau, making the automation sector one to watch. Companies enabling robotics and automation such as Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>), ABB (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ABBNY#OTC">ABBNY</a>), Rockwell Automation&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROK#NYSE">ROK</a>), Zebra Technologies&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZBRA#NASDAQ">ZBRA</a>), Teradyne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TER#NASDAQ">TER</a>) and UiPath (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) come to mind.
<h2 class="wp-block-heading">Energy Independence Goes Nuclear</h2>
Energy's next frontier? Nuclear. With mega-cap tech giants eyeing modular nuclear reactors as a green and reliable power source, demand for uranium is heating up. Beyond the U.S., countries like Japan and Germany are also jumping on the nuclear bandwagon, signaling a global shift toward energy resilience.
U.S. companies such as Constellation Energy&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEG#NASDAQ">CEG</a>), Cameco&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCJ#NYSE">CCJ</a>) and NuScale Power&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMR#NYSE">SMR</a>) come to mind.
Helfstein's roadmap suggests a year of targeted strategies. By aligning portfolios with these U.S.-centric themes, investors might not just weather volatility—they could thrive in the chaos.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/etfs/specialty-etfs/24/12/42437267/berkshire-palantir-etfs-add-high-octane-trading-options-with-direxions-launch">Berkshire, Palantir ETFs Add High-Octane Trading Options With Direxion&#8217;s Launch</a></li>
</ul>
Photo: Shutterstock

2025 Investment Themes: AI, Energy, Defense Redefine US Markets

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Keybanc raised the price target for Walmart Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) from $96 to $100. Keybanc analyst Bradley Thomas maintained an Overweight rating. Walmart shares closed at $94.55 on Tuesday. <a href="https://www.benzinga.com/quote/WMT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Truist Securities boosted the price target for Phreesia, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHR#NYSE">PHR</a>) from $31 to $34. Truist Securities analyst Jailendra Singh maintained a Buy rating. Phreesia shares closed at $24.14 on Tuesday. <a href="https://www.benzinga.com/quote/PHR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo cut RxSight, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXST#NASDAQ">RXST</a>) price target from $56 to $42. Wells Fargo analyst Larry Biegelsen downgraded the stock from Overweight to Equal-Weight. RxSight shares settled at $39.17 on Tuesday. <a href="https://www.benzinga.com/quote/RXST/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Oppenheimer increased Trimble Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRMB#NYSE">TRMB</a>) price target from $77 to $88. Oppenheimer analyst Kristen Owen maintained an Outperform rating. Trimble shares closed at $74.12 on Tuesday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Morgan Stanley cut Zenas BioPharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZBIO#NASDAQ">ZBIO</a>) price target from $40 to $35. Morgan Stanley analyst Vikram Purohit maintained an Overweight rating. Zenas BioPharma shares closed at $9.50 on Tuesday.  <a href="https://www.benzinga.com/quote/ZBIO/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Susquehanna boosted Visa Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>) price target from $339 to $375. Susquehanna analyst James Friedman maintained a Positive rating on the stock. Visa shares closed at $312.38 on Tuesday. See how other analysts view this stock.</li>
<li>Piper Sandler raised the price target for Synovus Financial Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNV#NYSE">SNV</a>) from $56 to $64. Piper Sandler analyst Brad Milsaps maintained an Overweight rating. Synovus Financial shares settled at $55.14 on Tuesday. <a href="https://www.benzinga.com/quote/SNV/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley boosted United Airlines Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>) price target from $88 to $130. Morgan Stanley analyst Ravi Shanker maintained an Overweight rating. United Airlines shares closed at $96.53 on Tuesday. <a href="https://www.benzinga.com/quote/UAL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo increased the price target for Intuitive Surgical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) from $549 to $630. Wells Fargo analyst Larry Biegelsen maintained an Overweight rating. Intuitive Surgical shares closed at $538.09 on Tuesday. <a href="https://www.benzinga.com/quote/ISRG/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Stifel raised Columbia Sportswear Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COLM#NASDAQ">COLM</a>) price target from $92 to $100. Stifel analyst Jim Duffy maintained a Buy rating. Columbia Sportswear shares closed at $90.09 on Tuesday. <a href="https://www.benzinga.com/quote/COLM/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42432935/top-3-health-care-stocks-that-may-collapse-this-quarter">Top 3 Health Care Stocks That May Collapse This Quarter</a></li>
</ul>

COLM

RXST

TRMB

ZBIO

Visa To Rally Over 20%? Here Are 10 Top Analyst Forecasts For Wednesday

Wells Fargo analyst Larry Biegelsen maintains Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) with a Overweight and raises the price target from $549 to $630.

Wells Fargo Maintains Overweight on Intuitive Surgical, Raises Price Target to $630

Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) has outperformed the market over the past 15 years by 8.62% on an annualized basis producing an average annual return of 20.53%. Currently, Intuitive Surgical has a market capitalization of $191.66 billion. 
Buying $1000 In ISRG: If an investor had bought $1000 of ISRG stock 15 years ago, it would be worth $16,578.15 today based on a price of $538.09 for ISRG at the time of writing.
<h3>Intuitive Surgical's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1733866213_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Intuitive Surgical 15 Years Ago Would Be Worth This Much Today

Analysis included 230 studies—a mix of randomized, prospective, and database research
SUNNYVALE, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>)
The peer-reviewed Annals of Surgery published <a href="https://www.globenewswire.com/Tracker?data=t_P3T_mDtq2kQ-Bi4_0x2CyvRROUzqRDr5pa0PuiyACM_QTjkCRQyPyAEmlDKODYWFaurEgI1IvSIuk_ZloeRopi6fr9lJwCP7rdbJ8vm50w1rzTyn8tQPVo9xwuDQyO1yA-xt7_gTqNpOitnCL6DWV_2TNfu8_y46YafHmT_sadf_imPZxoZm01Z4F2PqE0UTzwEOy3k0T34XXPgmE5RV7V2BJAPxch1JpAXkdpR2Hhznp4drDsZwdnGbb9-MAg94YzvWJWYI1rsdsMDa61XOlKF90Fbdfi-xsRjZAk7ug=">a meta-analysis of 30-day surgical outcomes across seven oncological surgical procedures</a>, comparing robotic, laparoscopic, and open surgical approaches. The study covered a 12-year timeframe and analyzed 230 studies from 22 countries: 34 randomized controlled trials, 74 prospective studies, and 122 database reviews. Each surgical approach represented more than a million procedures.
The meta-analysis, conducted by scientists from Intuitive and Massachusetts General Hospital, demonstrated multiple benefits for robotic surgery using Intuitive's da Vinci system as compared to laparoscopy and open surgery.

Biotech

Intuitive Surgical Announces The Peer-Reviewed Annals Of Surgery Published A Meta-Analysis Of 30-Day Surgical Outcomes Across Seven Oncological Surgical Procedures, Comparing Robotic, Laparoscopic, And Open Surgical Approaches

Intuitive Surgical's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NYSE">ISRG</a>) short percent of float has risen 7.34% since its last report. The company recently reported that it has 4.15 million shares sold short, which is 1.17% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.93 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Intuitive Surgical Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1733418014_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Intuitive Surgical has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Intuitive Surgical's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Intuitive Surgical's peer group average for short interest as a percentage of float is 4.04%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

(ISRG) - Analyzing Intuitive Surgical's Short Interest

Stifel analyst Rick Wise maintains Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) with a Buy and raises the price target from $525 to $610.

Stifel Maintains Buy on Intuitive Surgical, Raises Price Target to $610

Financial and Operational Highlights: Fourth quarter 2024 worldwide da Vinci procedures grew approximately 18% compared with the fourth quarter of ...

Intuitive Surgical reports preliminary Q4 revenue $2.41B, consensus $2.2B

Notable gainers among liquid option names this morning include Edison International (EIX) $62.60 +4.17, BNY Mellon (BK) $80.73 +4.79, Builders Firs...

Early notable gainers among liquid option names on January 15th

4 stocks to watch on Wednesday: JPM, BECN and more

ValuEngine's Top 10 Stocks For 2025

Intuitive Surgical, Inc. (ISRG) 43rd Annual J.P. Morgan Healthcare Conference (Transcript)

Stifel Nicolaus analyst Rick Wise has maintained their bullish stance on ISRG stock, giving a Buy rating yesterday. Rick Wise has given his Buy rat...

Intuitive Surgical's Bright Future: Strong Q4 Performance and Promising Outlook

In a report released yesterday, Larry Biegelsen from Wells Fargo maintained a Buy rating on Intuitive Surgical (ISRG – Research Report). The compan...

Wells Fargo Keeps Their Buy Rating on Intuitive Surgical (ISRG)

Travis Steed, an analyst from Bank of America Securities, maintained the Buy rating on Intuitive Surgical (ISRG – Research Report). The associated ...

Intuitive Surgical: Strong Financial Performance and International Growth Justify Buy Rating

Morgan Stanley keeps an Overweight rating and $650 price target on Intuitive Surgical (ISRG) after its Q4 pre-announcement, saying the company had ...

Intuitive Surgical had 'strong finish' to 2024, says Morgan Stanley

Truist Financial analyst Richard Newitter assigned a Buy rating to the stock today. The company's shares closed yesterday at $580.11. According to ...

Truist Financial Releases a Buy Rating on Intuitive Surgical (ISRG)

AFRM

BECN

BLDR

CHWY

CRDO

CVNA

DKNG

DOCU

OKTA

PYPL

ROKU

SPOT

TWLO

Untitled design - 2024-12-10T185819.364

Movers & Shakers

MBOT

Palm-Sized Innovation: How Microbot Medical Is Helping Redefine Surgical Robotics

Management

Press Releases

Intuitive President David J. Rosa Appointed to Intuitive Board of Directors

Neptune Medical Announces $97M Series D Financing and Spinout of Jupiter Endovascular

Jupiter Endovascular Exits Stealth With $21M in New Financing to Fund Pivotal Trial for Pulmonary Embolism

Intuitive Announces Third Quarter Earnings

Deborah Kilpatrick Joins Sonder Capital as its Newest Venture Partner

Artificial Intelligence (AI) Redefining Medical Diagnostics Industry That's Expected to be a $7.2 Billion Market by 2029

Meta-analysis published in Annals of Surgery shows benefits of da Vinci surgery across seven oncologic procedures compared to laparoscopic and open

Intuitive Announces Executive Leadership Changes to Support Continued Global Growth

Intuitive Announces Preliminary Fourth Quarter and Full Year 2024 Results

AVAI

PRCT

RHHBY

RXRX

SNBR

SWAV

Abbott Laboratories

Baxter Intl

Becton, Dickinson and Company Common Stock

Becton Dickinson

Boston Scientific Corporation Common Stock

Boston Scientific

DexCom

Edwards Lifesciences Corporation Common Stock

Edwards Lifesciences

GE HealthCare Technologies Inc. - Common Stock

GE HealthCare Techs

Glaukos

Globus Medical, Inc. Class A Common Stock

Globus Medical

Hologic

IDEXX Laboratories

Inspire Medical Systems, Inc. Common Stock

Inspire Medical Systems

Integer Holdings Corporation Common Stock

Integer Holdings

Masimo

Medtronic

Inari Medical

Penumbra

Koninklijke Philips N.V. NY Registry Shares

Koninklijke Philips

Insulet

ResMed

Smith & Nephew

Steris

Stryker

Teleflex

Zimmer Biomet Holdings, Inc. Common Stock

Zimmer Biomet Holdings

Truist Securities

Citigroup

Wells Fargo

Stifel

Morgan Stanley

수요일(15일) 미국 증시는 나스닥 종합지수가 2.45% 상승한 19,511.23포인트 S&amp;P 500 지수가 1.8% 상승한 5,949.91포인트를 기록하며 강세를 보였다. 다우존스 산업평균지수도 1.65% 상승한 43,221.55포인트를 기록했다.
하루 종일 소매 투자자와 트레이더의 주목을 받은 상위 종목은 다음과 같다.
<h3>1. 퀀텀 컴퓨팅 </h3>
수요일 퀀텀 컴퓨팅 주가는 55.45% 급등하여 11.55달러로 마감했다. 장중 최고가는 11.60달러, 최저가는 8.51달러였고, 52주 범위는 27.15~0.35달러였다.
이러한 급등은 3월 20일로 예정된 GTC 2025 행사에서 <a href="https://www.benzinga.com/25/01/43004816/whats-going-on-with-quantum-computing-stock-today">엔비디아의 첫 번째 &#8216;퀀텀 데이&#8217; 발표</a> 이후 나왔다. 이번 발표는 젠슨 황 CEO가 실용적인 양자 컴퓨팅은 아직 20년이 더 걸릴 수 있다고 언급한 직후에 이루어진 것이다. 또한 2025년까지 비즈니스 고객을 &#8216;퀀텀 레디&#8217;로 만들겠다는 마이크로소프트의 계획이 발표되어 기대감을 더했다.
<h3>2. TSMC</h3>
TSMC 주가는 2.61% 상승하여 206.80달러로 마감했다. 이날 거래는 최고가 209.04달러, 최저가 199.35달러이며, 52주 범위는 222.20~100달러였다.
TSMC는 곧 4분기 재무 실적을 발표할 예정이며, 애널리스트들은 5분기 연속 매출 상향을 예상하고 있다. 예상 매출은 262억 8,000만 달러로, 반도체 수요 강세와 미국 새로운 행정부의 <a href="https://www.benzinga.com/25/01/43015316/taiwan-semiconductor-q4-earnings-preview-analysts-expect-fifth-straight-beat-will-investors-get-comments-on-trump-impact">잠재적 수혜</a>에 힘입어 작년 같은 분기의 196억 2,000만 달러보다 증가할 것으로 예상된다.
<h3>3. 메타 플랫폼스</h3>
메타 플랫폼스 주가는 3.85% 상승하여 617.12달러에 마감했다. 장중 최고가 622.46달러, 최저가 606.50달러를 기록했으며, 52주 범위는 638.40~358.61달러였다.
내부 메모에 따르면 <a href="https://www.benzinga.com/media/25/01/42995912/meta-plans-to-cut-5-of-staff-backfill-roles-in-2025-says-internal-memo">성과 기반 감원 계획이</a> 공개되었으며, 이러한 전략에는 지난 1년간의 기여도에 따라 직원을 성과 등급으로 분류하는 것이 포함된다.
<h3>4. 인튜이티브 서지컬</h3>
인튜이티브 서지컬의 주가는 7.65% 상승하여 580.11달러에 마감했다. 장중 최고가 584.60달러, 최저가 549.17달러를 기록했으며, 52주 범위는 584.60~355.17달러였다.
이번 주가 상승은 인튜이티브 서지컬의 <a href="https://www.benzinga.com/news/earnings/25/01/43007218/why-intuitive-surgical-shares-are-surging-wednesday">4분기 예비 실적에</a> 따른 것으로, 예상 매출은 약 24억 1천만 달러로 애널리스트의 예상치인 22억 달러를 상회하는 것으로 나타났다. 또한 다빈치 로봇 시술(da Vinci procedure)과 시스템 배치가 크게 증가했다고 보고했다.
<h3>5. 테슬라</h3>
테슬라의 주가는 8.04% 상승하여 428.22로 마감했다. 이날 거래의 최고가는 429.80달러, 최저가는 405.66달러였고, 52주 범위는 488.54~138.80달러였다.
이러한 상승세는 최근 켈리블루북이 발표한 데이터에서 테슬라의 모델 Y와 모델 3가 가장 많이 팔린 전기자동차로 선정된 데 영향을 받았다. 2023년에 비해 2024년에 경쟁 심화로 인해 약 37,000대의 자동차를 덜 판매했음에도 불구하고 테슬라는 전기차 시장에서 <a href="https://www.benzinga.com/25/01/43014719/whats-going-on-with-tesla-shares-wednesday">선두를 유지했다</a>.
이미지 출처: Shutterstock
<a href="https://editorial.benzinga.com/wp-admin/Premarket%20Movers%20&amp;%20News">주요 프리마켓 주식 및 뉴스</a>를 벤징가에서 확인하고 하루의 거래를 준비하세요.
이 기사는 <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a>를 사용하여 생성되었으며, <a href="https://www.benzinga.com/author/shivdeep-dhaliwal">Shivdeep Dhaliwal</a>이 편집했습니다.
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

미국의 경쟁력은 2025년에 네 가지 주요 투자 테마인 에너지 독립, 방산 혁신, 인프라 및 자동화가 포트폴리오 성장을 강화할 태세를 갖추면서 중심 무대로 떠오른다. 스콧 헬프스타인(Scott Helfstein)이 이끄는 글로벌 X의 2025년 투자 전망은 이러한 변혁적인 트렌드를 <a href="https://www.benzinga.com/topic/us-economy" target="_blank" rel="noopener">향후 1년 동안</a>의 회복력의 중요한 동력으로 강조하고 있다.
<h2 class="wp-block-heading">인프라가 빛을 발산</h2>
미국의 인프라 르네상스가 본격화되면서 7,000억 달러의 지출이 건설, 장비 및 자재 회사에 활력을 불어넣을 예정이다. 이는 산업 선별 섹터 SPDR 펀드(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLI#NYSE">XLI</a>)에 투자하는 투자자에게 긍정적인 신호가 될 수 있다.
구경제의 강자들은 매력적인 밸류에이션으로 S&amp;P 500 전반에 비해 거래되면서 마진을 확대하기 위해 최첨단 기술로 재편되고 있다.
<h2 class="wp-block-heading">방산 분야: 전투기와 함정을 넘어서</h2>
글로벌 긴장이 전통적인 방산 플랫폼에서 인공지능(AI) 기반 드론과 사이버 보안 시스템과 같은 첨단 솔루션으로의 전환을 촉발하고 있다.
팔란티어 테크놀로지스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) 인공지능 플랫폼과 IBM(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>) 왓슨X AI가 여기에 해당한다.
방산 매출은 거의 10% 증가할 것으로 예상되며, 마진은 5.2%에서 7.6%로 상승할 것이다. 성공은 자동화와 차세대 기술을 채택하는 기업들에게 유리할 것이다.
참고: <a href="https://kr.benzinga.com/news/usa/stocks/%EC%A0%9C%EC%A1%B0%EC%97%85-%EB%B6%80%ED%99%9C-%EC%A0%84%EB%9E%B5%EA%B0%80-%EA%B4%80%EC%84%B8%EA%B0%80-%EC%86%8C%ED%98%95%EC%A3%BC%EC%97%90-%EB%8F%84%EC%9B%80%EC%9D%B4-%EB%90%98%EC%A7%80%EB%A7%8C/" target="_blank" rel="noopener">제조업의 재기? 전략가가 관세가 소형주에 도움을 줄 것이라고 예상하지만 소비자에게는 부담을 줄 것이라고 예상</a>
<h2 class="wp-block-heading">자동화 및 온쇼어링: 기술 혁명</h2>
미국이 온쇼어링 노력을 가속화함에 따라 자동화와 AI가 이 변화를 주도하는 핵심 요소로 부상하고 있다.
소프트웨어 회사들과 데이터 센터는 매출 급증을 준비하고 있으며, 메가 캡 기술 기업들은 데이터 센터에 대한 지출을 2025년까지 2,500억 달러로 늘리고 있다.
로봇 공학 및 IoT 하드웨어도 판매 정체에서 반등할 수 있어 자동화 부문은 주목할 만한 분야가 될 것이다. 엔비디아(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), 인튜이티브 서지컬(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>), ABB(OTC:<a class="ticker" href="https://www.benzinga.com/stock/ABBNY#OTC">ABBNY</a>), 로크웰 오토메이션(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROK#NYSE">ROK</a>), 지브라 테크놀로지스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZBRA#NASDAQ">ZBRA</a>), 테라다인(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TER#NASDAQ">TER</a>) 및 유아이패스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>)와 같은 회사들이 여기에 해당한다.
<h2 class="wp-block-heading">에너지 독립: 원자력으로 간다</h2>
에너지의 다음 경계는 무엇일까? 원자력이다. 메가 캡 기술 기업들이 모듈형 원자로를 친환경적이고 신뢰할 수 있는 전력원으로 주목하면서 우라늄 수요가 급증하고 있다. 미국을 넘어 일본과 독일과 같은 국가들도 원자력으로 전환하고 있어 에너지 회복력으로의 글로벌 전환을 알리고 있다.
콘스텔레이션 에너지(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEG#NASDAQ">CEG</a>), 카메코(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCJ#NYSE">CCJ</a>) 및 누스케일 파워(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMR#NYSE">SMR</a>)와 같은 미국 기업들이 떠오르고 있다.
헬프스타인의 로드맵은 목표 지향적인 전략의 한 해를 제안한다. 이러한 미국 중심의 테마와 포트폴리오를 정렬함으로써 투자자들은 변동성을 견뎌낼 뿐만 아니라 혼란 속에서 번창할 수 있을 것이다.

다음 읽기: 
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%EB%B2%84%ED%81%AC%EC%85%94%EC%99%80-%ED%8C%94%EB%9E%80%ED%8B%B0%EC%96%B4-etf%EB%93%A4-%EB%94%94%EB%A0%89%EC%8B%9C%EC%98%A8-%EC%B6%9C%EC%8B%9C%EB%A1%9C-%EA%B0%95%EB%A0%A5%ED%95%9C-%EA%B1%B0%EB%9E%98/" target="_blank" rel="noopener">버크셔, 팔란티어 ETF에 고옥탄 거래 옵션 추가</a></li>
</ul>
사진 출처: Shutterstock
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요. 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

매주, ‘벤징가의 스톡 위스퍼 지수(Benzinga's Stock Whisper Index)'는 독점 데이터(proprietary data)와 패턴 인식의 조합을 사용하여 <a href="https://www.benzinga.com/topic/stock-whisper-index" target="_blank" rel="noreferrer noopener">표면 바로 아래에서 주목</a>을 받을 만한 주식 5종목을 소개한다.
투자자들은 가치가 저평가된, 관심이 적은, 새로운 주식들을 항상 찾고 있다. 소매 거래자들이 사용할 수 있는 방법은 무수히 많기 때문에 새로운 기회를 발견하고 특정 주식이 관심을 가져야 하는 이유를 이해하기 위해 풍부한 정보를 조사하는 것이 어려운 경우가 많다.
다음은 11월 8일 주간 벤징가 ‘스톡 위스퍼' 지수의 개요:
인스메드 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>):
이 생명공학 회사는 10월 말에 3분기 재무 결과와 사업 업데이트를 <a href="https://investor.insmed.com/2024-10-31-Insmed-Reports-Third-Quarter-2024-Financial-Results-and-Provides-Business-Update" target="_blank" rel="noopener">발표</a>한 후 투자자들의 관심이 증가하고 있다. 이 회사는 아리케이스(ARIKAYCE)의 매출이 3분기에 9,340만 달러로 전년 대비 18% 증가했다고 밝혔다.
인스메드는 또한 기관지 확장증 치료제 브렌소카팁(Brensocatib)에 대한 NDA 제출이 4분기에 예정되어 있으며, 2025년 중반에 미국에서 출시될 것으로 예상된다고 밝혔다.
H.C. 웨인라이트는 분기 실적 발표 후 주식에 대해 매수 등급과 90달러의 목표 주가를 재확인했다. 트루이스트(Truist)는 매수 등급을 재확인하고 목표 주가를 100달러에서 105달러로 상향 조정했다. 이 회사는 11월 11일에 구겐하임(Guggenheim), 11월 12일 UBS 글로벌, 11월 20일 울프 리서치(Wolfe Research) 및 11월 21일 제프리스(Jefferies)를 포함한 여러 컨퍼런스에 참여할 예정이어서 앞으로 몇 주 안에 투자자들의 관심이 증가할 수 있다.
인스메드 주식은 최근 5일 거래일 동안 9% 이상 상승했으며, 2024년 연초 대비 145% 이상 상승했다.
<img decoding="async" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08135456/Screenshot-234.png?optimize=medium&amp;dpr=1.25&amp;auto=webp&amp;width=2048" />
어플라이드 인더스트리얼 테크놀로지스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIT#NYSE">AIT</a>):
이 산업 회사는 도널드 트럼프가 <a href="https://www.benzinga.com/news/24/11/41768178/donald-trump-defeats-kamala-harris-to-win-2024-election" target="_blank" rel="noopener">2024년 선거</a>에서 승리하는 것과 관련이 있을 수 있는 독자들의 강한 관심을 본 분야의 여러 회사 중 하나였다. 산업 섹터는 트럼프 대통령의 백악관 <a href="https://www.benzinga.com/general/politics/24/11/41783357/how-did-s-p-500-sectors-perform-during-trumps-first-term-could-this-time-be-different" target="_blank" rel="noopener">재임 4년 동안</a> 최고 실적을 거둔 부문이었다.
또한 이 회사는 최근 1분기 재무 결과를 <a href="https://ir.applied.com/news/news-details/2024/Applied-Industrial-Technologies-Reports-Fiscal-2025-First-Quarter-Results/default.aspx" target="_blank" rel="noopener">발표</a>하여 주당 순이익이 2.36달러 그리고 매출이 11억 달러로, 스트리트 컨센서스 추정치인 22억 7천만 달러와 10억 9천만 달러를 각각 넘어섰다. 어플라이드 인더스트리얼은 또한 2025 회계연도 주당 이익 지침을 이전 지침인 9.20~9.95달러에서 9.25~10.00달러 범위로 상향 조정했다. 이는 월가의 추정치인 9.39달러보다 앞선 것이다.
이 분기 실적 발표 후 애널리스트들은 <a href="https://www.benzinga.com/quote/AIT/analyst-ratings" target="_blank" rel="noopener">목표 주가를 상향</a> 조정했다. 주식은 최근 5일 거래일 동안 16% 이상 상승했으며, 2024년 연초 대비 57% 이상 상승했다.
<img decoding="async" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08135510/Screenshot-236.png?optimize=medium&amp;dpr=1.25&amp;auto=webp&amp;width=2048" />
스프라우츠 파머스 마켓 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFM#NASDAQ">SFM</a>):
이 전문 식료품 소매업체는 벤징가 독자들 사이에서 강한 관심을 받았으며, 이는 <a href="https://investors.sprouts.com/news/news-details/2024/Sprouts-Farmers-Market-Inc.-Reports-Third-Quarter-2024-Results/default.aspx" target="_blank" rel="noopener">최근</a> 분기 실적 발표 후 주가가 52주 최고가로 거래되고 있는 것과 관련이 있다. 이 회사의 3분기 주당 순이익은 91센트와 매출 19억 달러로 스트리트 예상치인 주당 76센트와 18억 8천만 달러를 각각 웃돌았다.
이 회사는 3분기가 예외적이었다고 언급했으며, CEO 잭 싱클레어(Jack Sinclair)는 &#8220;견고한 방문객 성장&#8221;을 강조했다. 동일 매장 매출이 3분기 동안 8.4% 증가했다. 이 회사는 9개의 새로운 매장을 열어 23개 주에 428개의 매장을 운영하고 있다.
골드만삭스는 최근 주식에 대해 <a href="https://www.benzinga.com/quote/SFM/analyst-ratings" target="_blank" rel="noopener">매수 등급을 유지</a>하고 목표 주가를 127달러에서 159달러로 상향 조정했다. 웰스 파고는 주식에 대해 중립 등급을 유지하고 목표 주가를 90달러에서 130달러로 상향 조정했다.
주식은 최근 5일 거래일 동안 11% 이상 상승했으며, 2024년 연초 대비 195% 이상 상승했다.
<img decoding="async" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08135528/Screenshot-237.png?optimize=medium&amp;dpr=1.25&amp;auto=webp&amp;width=2048" />
인튜이티브 서지컬 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>):
이 의료 기기 회사는 지난주 독자들 사이에서 강한 관심을 받았으며, 주가가 금요일에 52주 최고가로 거래되고 있다.
이 회사는 최근 <a href="https://kr.benzinga.com/news/usa/stocks/%EC%9D%B8%ED%8A%9C%EC%9D%B4%ED%8B%B0%EB%B8%8C-%EC%84%9C%EC%A7%80%EC%BB%AC%EC%9D%98-%EC%A3%BC%EC%8B%9D%EC%9D%80-%EA%B0%95%EB%A0%A5%ED%95%9C-3%EB%B6%84%EA%B8%B0-%EC%8B%A4%EC%A0%81%EC%97%90-%EC%8B%9C/" target="_blank" rel="noopener">3분기 재무 결과</a>를 발표했으며, 매출이 20억 4천만 달러로 컨센서스 예상치인 20억 달러를 초과했고, 주당 순이익이 1.84달러로 컨센서스 예상치인 1.63달러를 초과했다. 인튜이티브 서지컬은 3분기 동안 전년 대비 17%의 매출 성장을 보고했으며, 전 세계 다 빈치(da Vinci) 수술 건수가 전년 대비 18% 증가했다.
이 회사는 3분기 동안 379개의 다 빈치 시스템을 설치했으며, 이는 이전 분기의 312개에서 증가한 수치이다. 3분기 말 기준으로 설치된 다 빈치 수술 시스템은 9,539개이다. 인튜이티브는 10월에 한국에서 다 빈치 5 수술 시스템에 대한 규제 승인을 받았다.
이 실적 발표 이후 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41406234/intuitive-surgical-posts-q3-earnings-beat-these-analysts-raise-forecasts-on-dv5-upt" target="_blank" rel="noopener" data-google-interstitial="false">여러 애널리스트들이 목표 주가를 상향</a> 조정했다. 애널리스트들은 회사의 최신 다 빈치 5 시스템이 더 많은 종류의 수술에 사용할 수 있어 성장 촉매제로 작용할 것으로 보고 있다. 인튜이티브 서지컬 주식은 최근 5일 거래일 동안 6.02% 상승했으며, 2024년 연초 대비 62.08% 상승했다.
<img decoding="async" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08135542/Screenshot-238.png?optimize=medium&amp;dpr=1.25&amp;auto=webp&amp;width=2048" />
뮬러 인더스트리즈 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MLI#NYSE">MLI</a>):
이 산업 회사는 트럼프의 2024년 대선 승리 가능성과 관련하여 증가한 관심과 주가 상승을 경험했다. 이 회사는 최근 3분기 순매출이 9억 9,780만 달러로 컨센서스 예상치인 9억 3,600만 달러를 초과했으며, 분기 주당 순이익이 1.48달러로 예상치인 1.32달러를 초과했다고 <a href="https://ir.muellerindustries.com/news/press-releases/detail/178/mueller-industries-inc-reports-third-quarter-2024-earnings" target="_blank" rel="noopener">발표</a>했다. 뮬러 인더스트리즈는 최근 인수한 사업과 분기 중 구리 가격 상승이 매출 성장에 기여했다고 밝혔다.
뮬러의 CEO인 그렉 크리스토퍼(Greg Christopher)는 &#8220;우리는 금리 인하와 인플레이션 완화, 선거 관련 불확실성의 해소가 더 안정적이고 유리한 환경을 만들어 줄 것으로 예상했다&#8221;고 말했다.
주식은 최근 5일 동안 15.89% 상승했으며, 2024년 연초 대비 102% 이상 상승했다.
<img decoding="async" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08135559/Screenshot-240.png?optimize=medium&amp;dpr=1.25&amp;auto=webp&amp;width=2048" />
다음 주 보고서를 계속 지켜봐 주시기 바랍니다. 여기에서 Benzinga Pro를 팔로우하여 모든 최신 헤드라인과 <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110824&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">시장을 움직이는 주요 스토리</a>를 확인하세요.
Photo: Benzinga
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

벤징가의 '스톡 위스퍼' 지수: 인스메드, 인튜이티브 서지컬, 뮬러 인더스트리즈 및 2종목

인공지능(AI)을 테마로 한 상장지수펀드(ETF)는 자산 운용사들이 <a href="https://www.benzinga.com/topic/artificial-intelligence" target="_blank" rel="noopener" data-google-interstitial="false">인공지능</a>을 둘러싼 관심이 높아지는 것을 활용하면서 상당한 급증을 목격하고 있다. 모닝스타(Morningstar)에 따르면 올해 AI 중심 ETF 24개 중 1/3 이상이 출시되었다.
무슨 일이 (What Happened): 지난주에만 인공 지능에 초점을 맞추기 위해 브랜드가 변경된 ETF를 포함해 3개의 새로운 ETF가 AI 부문에 진출했다고 월요일 로이터가 보도했다. AI ETF의 총 자산은 현재 45억 달러에 이르렀으며, 이는 원자력 테마 ETF가 보유한 55억 달러에 근접하고 대마초 부문의 13억 7천만 달러를 넘어섰다.
모닝스타의 수석 분석가인 다니엘 소티로프(Daniel Sotiroff)는 &#8220;그들의 수가 증가하고 있는 것에 놀랍지 않다&#8221;고 언급하면서, 산업의 빠른 속도가 빠른 수익을 원하는 투자자들을 끌어들인다고 강조했다.
참고: <a href="https://kr.benzinga.com/news/usa/stocks/11%EC%9B%94-%EA%B8%88%EB%A6%AC-%EC%9D%B8%ED%95%98-%EA%B1%B0%EC%9D%98-%EA%B2%B0%EC%A0%95-%EC%97%B0%EC%A4%80%EC%9D%98-%EB%A7%88%EC%A7%80%EB%A7%89-%EA%B2%B0%EC%A0%95-%EC%9D%B4%ED%9B%84-%EA%B0%80/" target="_blank" rel="noopener">11월 금리 인하가 거의 확정된 상황: 최근 연준 결정 이후 가장 많이 상승한 10개 주식</a>
Benzinga Pro 데이터에 따르면, 지난 1년 동안 AI 기반 ETF의 성과는 다음과 같다:
Global X Robotics and Artificial Intelligence ETF(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOTZ#NASDAQ">BOTZ</a>): 현재 순자산 25억 1천만 달러, 순자산 가치(NAV)가 31.59달러인 BOTZ는 40.39% 상승했다. AI 관련 주요 보유 종목으로는 엔비디아(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)와 생명공학 회사 인튜이티브 서지컬(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>)가 있다.
Global X Artificial Intelligence &amp; Technology ETF(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIQ#NASDAQ">AIQ</a>): 순자산 22억 7,000만 달러, NAV가 37.36달러인 AIQ는 43.64% 상승했다. 오라클(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>), 시스코 시스템즈(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>)및 메타 플랫폼스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>)는 이 ETF의 최고 AI 관련 자산 중 일부이다.
iShares US Technology ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IYW#NYSE">IYW</a>): IYW는 지난 1년 동안 50.72% 상승했다. 이 ETF는 155.42달러의 NAV와 192억 4천만 달러의 순자산을 보유하고 있으며, 애플(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), 엔비디아, 마이크로소프트(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) 및 브로드컴(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>)과 같은 기술 주식에도 투자할 수 있다. 이들 주식은 AI에 대한 관심 덕분에 눈부신 성장을 목격했다.
Fidelity MSCI Information Technology Index ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTEC#NYSE">FTEC</a>): 이 ETF는 48.55% 상승했으며, 애플, 마이크로소프트, 엔비디아, 알파벳 및 브로드컴과 같은 주식에 투자할 수 있다. 순자산은 120억 5천만 달러이다.
왜 중요한가 (Why It Matters): AI 테마 ETF의 급증은 인공지능 기술에 대한 수요 증가에 의해 주도되는 광범위한 추세의 일환이다. 최근 엔비디아가 잠시 애플을 제치고 <a href="https://www.benzinga.com/markets/equities/24/10/41551461/nvidia-overtakes-apple-as-worlds-most-valuable-company-again">세계에서 가장 가치 있는 회사</a>가 된 바 있다. 이는 AI 슈퍼컴퓨팅 칩에 대한 수요 증가에 의해 촉발된 것이다. 이는 기술 분야에서 AI의 중요성이 커지고 있음을 강조한다.
더욱이, <a href="https://www.benzinga.com/news/24/10/41351070/imf-warns-ai-in-stock-trading-can-boost-efficiency-but-warns-of-increased-market-volatility">국제통화기금</a>(IMF)는 AI가 시장 효율성을 높일 수 있는 잠재력을 가지고 있지만, 시장 변동성과 사이버 위협의 증가를 경고했다. IMF의 글로벌 금융 안정성 보고서는 AI 기반 거래가 시장을 혁신할 수 있다고 제안하지만, 그 채택은 여전히 제한적이라고 경고한다. 또한, 규제가 덜한 비은행 금융 중개 기관들로의 투자 이동 가능성에 대해 경고하여 시장 감독을 복잡하게 만들 수 있다.

다음 읽기:
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41517027/five-us-banks-face-billions-in-losses-as-silvers-price-spike-hits-short-sellers-hard-report?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">5개 미국 은행, 은 가격 급등으로 공매도 투자자에게 타격: 수십억 달러 손실 직면</a></li>
</ul>
면책사항: 이 내용은 일부가 <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>의 도움을 받아 작성되었으며, Benzinga 편집자에 의해 검토 및 게시되었습니다.
사진 제공: Unsplash
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요. 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Intuitive Surgical

뉴스

에 대한 최신 뉴스 Intuitive Surgical (NASDAQ:ISRG) 주식

목요일, 1월 16, 2025

목요일, 12월 12, 2024

토요일, 11월 09, 2024

월요일, 10월 28, 2024

목요일, 10월 17, 2024

목요일, 7월 25, 2024

금요일, 4월 19, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌